NCT03948529 2025-09-30
REGALIA
University Hospital, Lille
Phase 2 Terminated
Clinical Trials
19 trialsNCT06630221 2025-07-03
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT03603795 2024-10-29
EPAG2015
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT02446145 2024-03-29
DELTA
Technische Universität Dresden
Phase 2 Terminated
NCT01428635 2023-09-26
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT01168921 2023-03-23
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01550185 2022-07-22
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Terminated
NCT02071901 2021-12-01
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT01113502 2021-08-05
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT02323178 2021-04-20
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Groupe Francophone des Myelodysplasies
Phase 1/2 Completed
NCT01656252 2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2 Terminated
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02010645 2020-01-02
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03701217 2018-10-09
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT01610180 2018-07-16
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01757145 2015-06-19
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Rabin Medical Center
Phase 2 Unknown
NCT01397149 2015-05-28
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
University of Ulm
Phase 1/2 Terminated